- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Revive Therapeutics Appoints Scientific Advisor for Cannabinoid-Based Therapeutics
Revive Therapeutics announced Dr. Ram Subramanian will join the company as a scientific advisor for their cannabinoid-based therapeutics targeting liver diseases.
Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) announced Dr. Ram Subramanian will join the company as a scientific advisor for their cannabinoid-based therapeutics targeting liver diseases.
As quoted in the press release:
“I am pleased that Dr. Subramanian has joined Revive to assist with advancing the research and clinical development of our cannabinoid-based research initiatives targeting liver diseases,” said Craig Leon, Chief Executive Officer of Revive. “Dr. Subramanian will be instrumental in guiding our research and clinical development initiatives in the field of liver disease.”
“I look forward to working with Revive in their objective of advancing novel cannabinoid-based therapeutic opportunities that address the unmet medical needs in liver diseases,” said Dr. Ram Subramanian.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.